Newsletter - Banner

Breadcrumb

Asset Publisher

angle-left Predicting Breast Cancer Metastasis to the Lung and Liver with Biomarkers

RI-MUHC researcher Peter Siegel and research associate Sébastien Tabariès have identified a key component of breast cancer metastasis to the liver and lung

April 4, 2019

Source: MedE-News. For about 20 to 30 percent of breast cancer patients, their primary tumour will spread to other organs such as the bones, lungs, liver, or brain. Remarkably, this metastasis to other organs accounts for 90 percent of deaths during breast cancer treatment. Unfortunately, many of the specific cellular processes regulating breast cancer metastasis are poorly understood and there are currently no targeted treatments. In a recent paper, published in the journal Genes & Development, scientists at the McGill University Faculty of Medicine’s Goodman Cancer Research Centre have identified potential metastatic biomarkers and a key component of breast cancer metastasis to the liver and lung. 

The senior author of the paper, Peter Siegel, PhD, is also a member of the Cancer Research Program at the Research Institute of the McGill University Health Centre. His research associate, Sébastien Tabariès, is lead author. Read more

Peter Siegel, PhD (left), member of the Research Institute of the MUHC and Goodman Cancer Research Centre, and research associate Sébastien Tabariès